AIM ImmunoTech Inc. 8-K

What Happened
AIM ImmunoTech Inc. announced on June 9, 2026 that it entered a securities purchase agreement for a registered direct offering and a concurrent private placement. The Registered Offering consists of 2,554,119 shares of common stock at $0.5189 per share (expected gross proceeds ≈ $1.3M). In the concurrent private placement the company sold 771,503 additional shares, issued pre-funded warrants to buy an aggregate 1,782,616 shares (exercise price $0.001, immediately exercisable, no expiration until fully exercised), and issued Class J warrants to purchase up to 10,216,476 shares (exercise price $0.5189). The Company and the investors expect the closing on or about June 10, 2026.

Key Details

• Offering price: $0.5189 per share for Offered Shares and Class J warrants; Pre-Funded Warrants exercise price $0.001.
• Registered shares: 2,554,119; Unregistered shares in private placement: 771,503.
• Warrants: Pre-Funded Warrant Shares = 1,782,616; Class J Warrant Shares = 10,216,476. If all warrants are exercised for cash, additional gross proceeds would be ≈ $5.3M (timing not guaranteed).
• Placement agent: Ladenburg Thalmann & Co. Inc.; fees = 8.0% cash fee + 0.75% management fee of gross proceeds; Placement Agent also received warrants to purchase 306,494 shares (6% of aggregate), exercisable at $0.6486 and expiring five years from the offering start.
• Registration: Company agreed to file a resale registration statement (Form S-1) within 10 days of closing and to use commercially reasonable efforts to have it effective within 60 days (90 days if full SEC review). Cashless exercise permitted if registration/resale prospectus is not available.

Why It Matters
This financing raises near-term capital (≈ $1.3M gross now) and creates the potential for further funding (≈ $5.3M) if warrants are exercised, but actual cash depends on future exercises. The transactions introduce a significant number of potential shares via warrants, which may dilute existing shareholders if exercised. Investors should note the placement agent’s cash and warrant compensation (which further dilutes) and the requirement that Class J warrants only become exercisable after stockholder approval of the underlying share issuance. The timing and cash benefits from these warrants are uncertain and depend on future filings, registration effectiveness, and investor exercise decisions.